GlucoVIP - Diabetes Treatment by Glucobay® With a Special Therapeutic View to Chosen Patient Groups
Tracking Information
Start Date ICMJE | May 2009 |
---|---|
Estimated Primary Completion Date | December 2010 (final data collection date for primary outcome measure) |
Current Primary Outcome Measures ICMJE | |
Original Primary Outcome Measures ICMJE (submitted: May 26, 2009) | Data collection on patients weight and waist circumference, fasting blood glucose, postprandial blood glucose (2h), HbA1C; exploratory analysis according to patient groups (concomitant cardiovascular disease groups, BMI) [ Time Frame: During observation period of three months ] [ Designated as safety issue: No ] |
Change History | Complete list of historical versions of study NCT00909051 on ClinicalTrials.gov Archive Site |
Descriptive Information
Brief Title ICMJE | GlucoVIP - Diabetes Treatment by Glucobay® With a Special Therapeutic View to Chosen Patient Groups |
---|---|
Official Title ICMJE | Diabetes Treatment by Glucobay® With a Special Therapeutic View to Chosen Patient Groups |
Brief Summary | Evaluation of safety and effectiveness of Glucobay® under daily-life treatment conditions in a large sample of patients. |
Detailed Description | |
Study Phase | |
Study Type ICMJE | Observational |
Study Design ICMJE | Cohort, Prospective |
Condition ICMJE | Diabetes Mellitus |
Intervention ICMJE | Drug: Acarbose, Glucobay (BAYG5421) Patients with diabetes type 2 newly treated with Glucobay |
Study Arms / Comparison Groups | Group 1 Intervention: Drug: Acarbose, Glucobay (BAYG5421) |
Recruitment Information
Estimated Enrollment ICMJE | 17000 | ||||
---|---|---|---|---|---|
Estimated Completion Date | December 2010 | ||||
Estimated Primary Completion Date | December 2010 (final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| ||||
Gender | Both | ||||
Ages | 18 Years and older | ||||
Accepts Healthy Volunteers | No | ||||
Contacts ICMJE |
| ||||
Location Countries ICMJE | Bosnia and Herzegovina, Cambodia, China, Hong Kong, India, Indonesia, Korea, Republic of, Malaysia, Moldova, Republic of, Pakistan, Philippines, Russian Federation, Singapore, Thailand, Vietnam |
Administrative Information
NCT ID ICMJE | NCT00909051 | ||||
---|---|---|---|---|---|
Responsible Party | Medical Affairs Therapeutic Area Head, Bayer Schering Pharma AG | ||||
Study ID Numbers ICMJE | 14284, GB 0701 | ||||
Study Sponsor ICMJE | Bayer | ||||
Collaborators ICMJE | |||||
Investigators ICMJE |
| ||||
Information Provided By | Bayer |
Source: http://clinicaltrials.gov/